Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 28 systematic review(s)/meta-analysis(es). ^[1-28]
• Lurasidone significantly improved the Montgomery Asberg Depression Rating Scale (MADRS) score versus placebo (-4.71, 95% CrI -6.98 to -2.41) and showed higher response (RR (relative risk) 0.78, 95% CI (confidence interval) 0.66 to 0.92) and remission rates (RR 0.90, 95% CI 0.83 to 0.98).
• In Clinical Global Improvement - Bipolar Disorder (CGI-BP) scores, lurasidone demonstrated greater efficacy compared to cariprazine and ziprasidone but similar outcomes to quetiapine and olanzapine.
• Lurasidone displayed superior odds of response versus cariprazine, aripiprazole, and ziprasidone and was effective in adolescents, showing significant improvements in PANSS and CGI-S scores for schizophrenia and comparable efficacy to olanzapine-fluoxetine in bipolar depression.
• Lurasidone effectively prevented mood episode recurrence when combined with mood stabilizers and had lower odds of all-cause discontinuation compared to aripiprazole and paliperidone ER.
• Lurasidone demonstrated minimal weight change (0.34 kg [95% CrI -0.22, 0.89]) relative to placebo and showed significantly less weight gain than olanzapine and quetiapine. In adolescent populations, lurasidone was associated with lower weight gain compared to other antipsychotics.
• Lurasidone had lower increases in cholesterol and triglycerides than olanzapine and quetiapine, with minimal effects on glucose and prolactin levels.
• Adverse events associated with lurasidone included a higher incidence of akathisia, nausea, and somnolence compared to placebo, with a similar safety profile to other antipsychotics in terms of extrapyramidal symptoms (EPS) and akathisia rates.
• Lurasidone was effective and well-tolerated in adolescents with schizophrenia, showing significant improvements in PANSS and CGI-S scores, and exhibited a favorable safety profile with lower weight gain compared to other antipsychotics.